The largest clinical trial program of patients with hemophilia A with and without FVIII inhibitors 6-13

The 373 people included the following ages:

Benefit was evaluated in 373 people, and safety analysis included a dose-finding trial of an additional 18 people.

HAVEN 3 

HAVEN 2 

HAVEN 1

BPAs=bypassing agents; FVIII=factor VIII; QW=once a week; Q2W=every 2 weeks.

Efficacy in Patients Without Inhibitors

Learn about the primary and secondary results for patients without FVIII inhibitors

Efficacy in Patients With Inhibitors

Learn about the primary and secondary results for patients with FVIII inhibitors

Contact a Rep

Get in touch with your HEMLIBRA representative